Babl Franz E, Pelton Stephen I, Li Zhong
Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Antimicrob Agents Chemother. 2002 Jul;46(7):2194-9. doi: 10.1128/AAC.46.7.2194-2199.2002.
Treatment of acute otitis media (AOM) with azithromycin results in apparent clinical success, but tympanocentesis performed 4 to 6 days after initiation of therapy in children with nontypeable Haemophilus influenzae (NTHI) recovered from initial middle ear cultures demonstrates persistence of infection in more than 50% of episodes. We sought to determine the effect of azithromycin at different doses on the density of middle ear infection due to NTHI to provide additional understanding of this dichotomy between clinical and microbiologic outcome measures in AOM. In a chinchilla model of experimental otitis media (EOM), animals treated with placebo were compared to animals receiving a single daily dose 30 or 120 mg of azithromycin per kg of body weight per day for 5 days. Microbiologic outcome was assessed by obtaining quantitative cultures from the middle ear during a 5-day course and for 1 week following therapy. Azithromycin concentrations were measured to ascertain whether a concentration-dependent effect was present. Azithromycin at 30 and 120 mg/kg/day demonstrated a dose-dependent effect on the quantitative assessment of middle ear infection due to NTHI. A 30-mg/kg dose of azithromycin daily resulted in levels in serum and areas under the serum concentration-time curve at 24 h comparable to published data obtained with children given azithromycin at 5 to 10 mg/kg in multiday regimens. Increased doses of azithromycin (120 mg/kg) achieved 2.5- to 4-fold-higher levels in serum and 3- to 6-fold-higher total levels and levels in extracellular middle ear fluid as well as more rapid reduction in bacterial density and a greater proportion of middle ears with complete sterilization than either placebo or the 30-mg/kg/day regimen.
用阿奇霉素治疗急性中耳炎(AOM)可取得明显的临床成功,但在最初中耳培养中分离出不可分型流感嗜血杆菌(NTHI)的儿童中,在治疗开始后4至6天进行鼓室穿刺术发现,超过50%的病例感染持续存在。我们试图确定不同剂量的阿奇霉素对NTHI引起的中耳感染密度的影响,以进一步了解AOM临床和微生物学结果指标之间的这种差异。在一个实验性中耳炎(EOM)的龙猫模型中,将接受安慰剂治疗的动物与每天接受30或120毫克/千克体重阿奇霉素单次剂量治疗5天的动物进行比较。通过在5天疗程期间以及治疗后1周从中耳获取定量培养物来评估微生物学结果。测量阿奇霉素浓度以确定是否存在浓度依赖性效应。30和120毫克/千克/天的阿奇霉素对NTHI引起的中耳感染定量评估显示出剂量依赖性效应。每天30毫克/千克剂量的阿奇霉素导致血清水平以及24小时血清浓度-时间曲线下面积与已发表的关于儿童多日服用5至10毫克/千克阿奇霉素的数据相当。增加阿奇霉素剂量(120毫克/千克)可使血清水平提高2.5至4倍,总水平和细胞外中耳液水平提高3至6倍,细菌密度降低更快,与安慰剂或30毫克/千克/天的治疗方案相比,中耳完全灭菌的比例更高。